간행물

생화학분자생물학회입니다.


EMM

Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases

  • 작성자

    KyeongJin Kim
  • 작성일자

    2023-12-21
  • 조회수

    565
KyeongJin Kim( kimkj@inha.ac.kr )
2019-presentAssistant/Associate Professor, Department of Biomedical Sciences,
Inha University
2013-2019Postdoctoral/Associate Research Scientist, Columbia University
2010-2013Postdoctoral Fellow, Sungkyunkwan University
2000-2010BS/MS/PhD, Department of Molecular Biology,
Pusan National University

Targeting E3 ubiquitin ligases and their adaptors as a therapeutic strategy for metabolic diseases

Posttranslational modification of proteins via ubiquitination determines their activation, translocation, dysregulation, or degradation. This process targets a large number of cellular proteins, affecting all biological pathways involved in the cell cycle, development, growth, and differentiation. Thus, aberrant regulation of ubiquitination is likely associated with several diseases, including various types of metabolic diseases. Among the ubiquitin enzymes, E3 ubiquitin ligases are regarded as the most influential ubiquitin enzymes due to their ability to selectively bind and recruit target substrates for ubiquitination. Continued research on the regulatory mechanisms of E3 ligases and their adaptors in metabolic diseases will further stimulate the discovery of new targets and accelerate the development of therapeutic options for metabolic diseases. In this review, based on recent discoveries, we summarize new insights into the roles of E3 ubiquitin ligases and their adaptors in the pathogenesis of metabolic diseases by highlighting recent evidence obtained in both human and animal model studies.

Exp Mol Med. 2023; 55(10): 2097-2014. doi: 10.1038/s12276-023-01087-w.
https://pubmed.ncbi.nlm.nih.gov/37779139/